uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Ljunggren, Östen
Alternative names
Publications (10 of 122) Show all publications
Zillikens, M. C., Demissie, S., Hsu, Y.-H., Yerges-Armstrong, L. M., Chou, W.-C., Stolk, L., . . . Kiel, D. P. (2017). Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 8, Article ID 80.
Open this publication in new window or tab >>Large meta-analysis of genome-wide association studies identifies five loci for lean body mass
Show others...
2017 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 8, 80Article in journal (Refereed) Published
Abstract [en]

Lean body mass, consisting mostly of skeletal muscle, is important for healthy aging. We performed a genome-wide association study for whole body (20 cohorts of European ancestry with n = 38,292) and appendicular (arms and legs) lean body mass (n = 28,330) measured using dual energy X-ray absorptiometry or bioelectrical impedance analysis, adjusted for sex, age, height, and fat mass. Twenty-one single-nucleotide polymorphisms were significantly associated with lean body mass either genome wide (p < 5 x 10(-8)) or suggestively genome wide (p < 2.3 x 10(-6)). Replication in 63,475 (47,227 of European ancestry) individuals from 33 cohorts for whole body lean body mass and in 45,090 (42,360 of European ancestry) subjects from 25 cohorts for appendicular lean body mass was successful for five single-nucleotide polymorphisms in/ near HSD17B11, VCAN, ADAMTSL3, IRS1, and FTO for total lean body mass and for three single-nucleotide polymorphisms in/ near VCAN, ADAMTSL3, and IRS1 for appendicular lean body mass. Our findings provide new insight into the genetics of lean body mass.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP, 2017
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-332854 (URN)10.1038/s41467-017-00031-7 (DOI)000405818900003 ()28724990 (PubMedID)
Funder
Swedish Research CouncilSwedish Foundation for Strategic Research Torsten Söderbergs stiftelseRagnar Söderbergs stiftelse
Available from: 2017-11-08 Created: 2017-11-08 Last updated: 2017-11-29Bibliographically approved
Lewerin, C., Ljunggren, Ö., Nilsson-Ehle, H., Karlsson, M. K., Herlitz, H., Lorentzon, M., . . . Mellström, D. (2017). Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study. Bone, 98, 1-8.
Open this publication in new window or tab >>Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study
Show others...
2017 (English)In: Bone, ISSN 8756-3282, E-ISSN 1873-2763, Vol. 98, 1-8 p.Article in journal (Refereed) Published
Abstract [en]

Background: Fibroblast growth factor (FGF23) is a protein that is produced by osteoblasts and osteocytes. Increased serum levels of FGF23 have been associated with increased risks of osteoporotic fractures and cardiovascular disease, particularly in participants with poor renal function. Serum iron (Fe) has been suggested as a regulator of FGF23 homeostasis. Objective: To determine whether Fe and iron status are determinants of the levels of intact FGF23 (iFGF23) in elderly men. Methods: The MrOS study is a population-based study of elderly men (N = 1010; mean age, 75.3 years; range, 69-81 years). The levels of Fe, transferrin saturation (TS), and ferritin were evaluated in relation to the serum concentrations of iFGF23 before and after adjustments for confounders. Results: TS<15% was found in 3.5% (34/977) of the participants, who had a higher median level iFGF23 compared with the remaining subjects (47.4 mu rnol/L vs. 41.9 mu mol/L, p = 0.008). The levels of iFGF23 correlated negatively (un-adjusted) with the levels of Fe (r = -0.17, p < 0.001), TS (r = -0.16, p < 0.001) and serum ferritin (r = -0.07, p = 0.022). In addition, in participants with estimated glomerular filtration rate eGFRCystatin C > 60 mL/min, the levels of iFGF23 correlated (age-adjusted) negatively with the levels of Fe (r = -0.15, p < 0.001) and TS (r = -0.17, p < 0.001). The level of iFGF23 correlated positively (un-adjusted) with lumbar spine bone mineral density (BMD) (r = 0.14, p < 0.001), total body BMD (r = 0.11, p = 0.001), and total hip BMD (r = 0.09, p = 0.004). The corresponding correlations, when adjusted for age, weight, and height were: r = 0.08, p = 0.018; r = 0.05, p = 0.120; and r = 0.02, p = 0.624, respectively. No associations were found between BMD and the levels of Fe or TS. Multiple step-wise linear regression analyses [adjusting for age, body mass index (BMI), comorbidity index, cystatin C, C-reactive protein (hs-CRP), serum vitamin D 25-OH (25OHD), phosphate, calcium, parathyroid hormone (PTH), erythropoietin, hemoglobin, lumbar spine BMD, apolipoprotein B/A1 ratio] were performed in three separate models with Fe, TS or ferritin as potential explanatory variables. Fe and TS, but not ferritin, were independent predictors of iFGF23 level (standardized beta-values: -0.10, p <0.001; 0.10, p <0.001; and -0.05, p = 0.062, respectively). Conclusion: Low levels of Fe in elderly men are associated with high levels of iFGF23, independently of markers of inflammation and renal function, suggesting an iron-related pathway for FGF23 regulation. (C) 2017 Elsevier Inc. All rights reserved.

Place, publisher, year, edition, pages
Elsevier, 2017
Keyword
Elderly, Men, Iron, Fibroblast growth factor 23, Intact FGF23, Bone mineral density
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-322679 (URN)10.1016/j.bone.2017.02.005 (DOI)000400227800001 ()28212898 (PubMedID)
Available from: 2017-05-29 Created: 2017-05-29 Last updated: 2017-05-29Bibliographically approved
Vandenput, L., Mellstrom, D., Laughlin, G. A., Cawthon, P. M., Cauley, J. A., Hoffman, A. R., . . . Ohlsson, C. (2017). Low Testosterone, but Not Estradiol, Is Associated With Incident Falls in Older Men: The International MrOS Study. Journal of Bone and Mineral Research, 32(6), 1174-1181.
Open this publication in new window or tab >>Low Testosterone, but Not Estradiol, Is Associated With Incident Falls in Older Men: The International MrOS Study
Show others...
2017 (English)In: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 32, no 6, 1174-1181 p.Article in journal (Refereed) Published
Abstract [en]

Fracture risk is determined by bone strength and the risk of falls. The relationship between serum sex steroids and bone strength parameters in men is well known, whereas the predictive value of sex steroids for falls is less studied. The aim of this study was to assess the associations between serum testosterone (T) and estradiol (E2) and the likelihood of falls. Older men (aged > 65 years) from the United States (n = 1919), Sweden (n = 2495), and Hong Kong (n = 1469) participating in the Osteoporotic Fractures in Men Study had baseline T and E2 analyzed by mass spectrometry. Bioavailable (Bio) levels were calculated using mass action equations. Incident falls were ascertained every 4 months during a mean follow-up of 5.7 years. Associations between sex steroids and falls were estimated by generalized estimating equations. Fall rate was highest in the US and lowest in Hong Kong (US 0.50, Sweden 0.31, Hong Kong 0.12 fall reports/person/year). In the combined cohort of 5883 men, total T (odds ratio [OR] per SD increase = 0.88, 95% confidence interval [CI] 0.86-0.91) and BioT (OR = 0.86, 95% CI 0.83-0.88) were associated with incident falls in models adjusted for age and prevalent falls. These associations were only slightly attenuated after simultaneous adjustment for physical performance variables (total T: OR = 0.94, 95% CI 0.91-0.96; BioT: OR = 0.91, 95% CI 0.89-0.94). E2, BioE2, and sex hormone-binding globulin (SHBG) were not significantly associated with falls. Analyses in the individual cohorts showed that both total T and BioT were associated with falls in MrOS US and Sweden. No association was found in MrOS Hong Kong, and this may be attributable to environmental factors rather than ethnic differences because total T and BioT predicted falls in MrOS US Asians. In conclusion, low total T and BioT levels, but not E2 or SHBG, are associated with increased falls in older men.

Keyword
SEX STEROIDS, FALLS, PHYSICAL PERFORMANCE, GENERAL POPULATION STUDIES, MEN
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-329695 (URN)10.1002/jbmr.3088 (DOI)000403220400005 ()28135013 (PubMedID)
Funder
Swedish Research CouncilSwedish Foundation for Strategic Research Torsten Söderbergs stiftelseRagnar Söderbergs stiftelseNovo Nordisk
Available from: 2017-10-10 Created: 2017-10-10 Last updated: 2017-10-10Bibliographically approved
Holgersson, M. B., Ruhayel, Y., Karlsson, M., Giwercman, A., Bjartell, A., Ohlsson, C., . . . Giwercman, Y. L. (2017). Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele. Cancer Causes and Control, 28(3), 227-233.
Open this publication in new window or tab >>Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
Show others...
2017 (English)In: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 28, no 3, 227-233 p.Article in journal (Refereed) Published
Abstract [en]

In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Using data from two population-based cohorts; the Malmo Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45-0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47-1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51-0.90; p = 0.008). Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.

Place, publisher, year, edition, pages
SPRINGER, 2017
Keyword
Androgen receptor, Prostate cancer, Genetic variants
National Category
Cancer and Oncology Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:uu:diva-320347 (URN)10.1007/s10552-017-0859-1 (DOI)000394986000005 ()28176139 (PubMedID)
Funder
Swedish Cancer Society, CAN 2014/360
Available from: 2017-04-19 Created: 2017-04-19 Last updated: 2017-04-19Bibliographically approved
Kherad, M., Rosengren, B. E., Hasserius, R., Nilsson, J.-A., Redlund-Johnell, I., Ohlsson, C., . . . Karlsson, M. K. (2017). Risk factors for low back pain and sciatica in elderly men-the MrOS Sweden study. Age and Ageing, 46(1), 64-71.
Open this publication in new window or tab >>Risk factors for low back pain and sciatica in elderly men-the MrOS Sweden study
Show others...
2017 (English)In: Age and Ageing, ISSN 0002-0729, E-ISSN 1468-2834, Vol. 46, no 1, 64-71 p.Article in journal (Refereed) Published
Abstract [en]

Introduction: the aim of this study was to identify whether factors beyond anatomical abnormalities are associated with low back pain (LBP) and LBP with sciatica (SCI) in older men. Material and methods: Mister Osteoporosis Sweden includes 3,014 men aged 69-81 years. They answered questionnaires on lifestyle and whether they had experienced LBP and SCI during the preceding 12 months. About 3,007 men answered the back pain (BP) questions, 258 reported BP without specified region. We identified 1,388 with no BP, 1,361 with any LBP (regardless of SCI), 1,074 of those with LBP also indicated if they had experienced LBP (n = 615), LBP+ SCI (n = 459). Results: about 49% of those with LBP and 54% of those with LBP+ SCI rated their health as poor/very poor (P < 0.001). Men with any LBP to a greater extent than those without BP had poor self-estimated health, depressive symptoms, dizziness, fall tendency, serious comorbidity (diabetes, stroke, coronary heart disease, pulmonary disease and/or cancer) (all P < 0.001), foreign background, were smokers (all P < 0.01), had low physical activity and used walking aids (all P < 0.05). Men with LBP+ SCI to a greater extent than those with LBP had lower education, lower self-estimated health, comorbidity, dizziness and used walking aids (all P < 0.001). Conclusions: in older men with LBP and SCI, anatomical abnormalities such as vertebral fractures, metastases, central or lateral spinal stenosis or degenerative conditions may only in part explain prevalent symptoms and disability. Social and lifestyle factors must also be evaluated since they are associated not only with unspecific LBP but also with LBP with SCI.

Place, publisher, year, edition, pages
OXFORD UNIV PRESS, 2017
Keyword
cross-sectional study, low back pain, men, older people, sciatica
National Category
Geriatrics
Identifiers
urn:nbn:se:uu:diva-320819 (URN)10.1093/ageing/afw152 (DOI)000398086600014 ()28181641 (PubMedID)
Available from: 2017-04-26 Created: 2017-04-26 Last updated: 2017-04-26Bibliographically approved
Orwoll, E. S., Lapidus, J., Wang, P. Y., Vandenput, L., Hoffman, A., Fink, H. A., . . . Ohlsson, C. (2017). The Limited Clinical Utility of Testosterone, Estradiol, and Sex Hormone Binding Globulin Measurements in the Prediction of Fracture Risk and Bone Loss in Older Men. Journal of Bone and Mineral Research, 32(3), 633-640.
Open this publication in new window or tab >>The Limited Clinical Utility of Testosterone, Estradiol, and Sex Hormone Binding Globulin Measurements in the Prediction of Fracture Risk and Bone Loss in Older Men
Show others...
2017 (English)In: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 32, no 3, 633-640 p.Article in journal (Refereed) Published
Abstract [en]

Measurement of serum testosterone (T) levels is recommended in the evaluation of osteoporosis in older men and estradiol (E2) and sex hormone binding globulin (SHBG) levels are associated with the rate of bone loss and fractures, but the clinical utility of sex steroid and SHBG measurements for the evaluation of osteoporosis in men has not been examined. To evaluate whether measurements of T, E2, and/or SHBG are useful for the prediction of fracture risk or the rate of bone loss in older men, we analyzed longitudinal data from 5487 community-based men participating in the Osteoporotic Fractures in Men (MrOS) study in the United States, Sweden, and Hong Kong. Serum T, E2, and SHBG levels were assessed at baseline; incident fractures were self-reported at 4-month intervals with radiographic verification (US), or ascertained via national health records (Sweden, Hong Kong). Rate of bone loss was assessed by serial measures of hip bone mineral density (BMD). We used receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) to assess improvement in prediction. Mean age at baseline was 72 to 75 years and the prevalence of low T levels (<300 ng/dL) was 7.6% to 21.3% in the three cohorts. There were 619 incident major osteoporotic and 266 hip fractures during follow-up of approximately 10 years. Based on ROC curves, there were no improvements in fracture risk discrimination for any biochemical measure when added to models, including the Fracture Risk Assessment Tool (FRAX) with BMD. Although minor improvements in NRI were observed for the dichotomous parameters low bioavailable E2 (BioE2) (<11.4 pg/mL) and high SHBG(>59.1 nM), neither sex steroids nor SHBG provided clinically useful improvement in fracture risk discrimination. Similarly, they did not contribute to the prediction of BMD change. In conclusion, there is limited clinical utility of serum E2, T, and SHBG measures for the evaluation of osteoporosis risk in elderly men.

Place, publisher, year, edition, pages
WILEY, 2017
Keyword
Fracture Risk Assessment, Osteoporosis, Aging, Epidemiology, Dxa
National Category
Endocrinology and Diabetes Nutrition and Dietetics
Identifiers
urn:nbn:se:uu:diva-320853 (URN)10.1002/jbmr.3021 (DOI)000398055900023 ()27753150 (PubMedID)
Funder
NIH (National Institute of Health), U01 AG027810 U01 AG042124 U01 AG042139 U01 AG042140 U01 AG042143 U01 AG042145 U01 AG042168 U01 AR066160 UL1 TR000128Swedish Research CouncilSwedish Foundation for Strategic Research Torsten Söderbergs stiftelseNovo Nordisk
Available from: 2017-04-26 Created: 2017-04-26 Last updated: 2017-04-26Bibliographically approved
McCloskey, E. V., Odén, A., Harvey, N. C., Leslie, W. D., Hans, D., Johansson, H., . . . Kanis, J. A. (2016). A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. Journal of Bone and Mineral Research, 31(5), 940-948.
Open this publication in new window or tab >>A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX
Show others...
2016 (English)In: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 31, no 5, 940-948 p.Article in journal (Refereed) Published
Abstract [en]

Trabecular bone score (TBS) is a grey-level textural index of bone microarchitecture derived from lumbar spine dual-energy X-ray absorptiometry (DXA) images. TBS is a BMD-independent predictor of fracture risk. The objective of this meta-analysis was to determine whether TBS predicted fracture risk independently of FRAX probability and to examine their combined performance by adjusting the FRAX probability for TBS. We utilized individual level data from 17,809 men and women in 14 prospective population-based cohorts. Baseline evaluation included TBS and the FRAX risk variables and outcomes during follow up (mean 6.7 years) comprised major osteoporotic fractures. The association between TBS, FRAX probabilities and the risk of fracture was examined using an extension of the Poisson regression model in each cohort and for each sex and expressed as the gradient of risk (GR; hazard ratio per 1SD change in risk variable in direction of increased risk). FRAX probabilities were adjusted for TBS using an adjustment factor derived from an independent cohort (the Manitoba Bone Density Cohort). Overall, the GR of TBS for major osteoporotic fracture was 1.44 (95% CI: 1.35-1.53) when adjusted for age and time since baseline and was similar in men and women (p > 0.10). When additionally adjusted for FRAX 10-year probability of major osteoporotic fracture, TBS remained a significant, independent predictor for fracture (GR 1.32, 95%CI: 1.24-1.41). The adjustment of FRAX probability for TBS resulted in a small increase in the GR (1.76, 95%CI: 1.65, 1.87 vs. 1.70, 95%CI: 1.60-1.81). A smaller change in GR for hip fracture was observed (FRAX hip fracture probability GR 2.25 vs. 2.22). TBS is a significant predictor of fracture risk independently of FRAX. The findings support the use of TBS as a potential adjustment for FRAX probability, though the impact of the adjustment remains to be determined in the context of clinical assessment guidelines.

Keyword
TRABECULAR BONE STRUCTURE; TBS; FRACTURE; RISK; FRAX; META-ANALYSIS
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-279299 (URN)10.1002/jbmr.2734 (DOI)000377270400004 ()26498132 (PubMedID)
External cooperation:
Funder
GlaxoSmithKline (GSK)NIH (National Institute of Health)
Available from: 2016-02-29 Created: 2016-02-29 Last updated: 2017-11-30Bibliographically approved
Borgström, F., Olafsson, G., Jonsson, E., Ström, O., Ljunggren, Ö., Akesson, K., . . . Kanis, J. A. (2016). A Simulation Model For The Treatment Pathway Of Osteoporosis. Paper presented at WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, APR 14-17, 2016, Malaga, SPAIN. Osteoporosis International, 27, S60-S60.
Open this publication in new window or tab >>A Simulation Model For The Treatment Pathway Of Osteoporosis
Show others...
2016 (English)In: Osteoporosis International, ISSN 0937-941X, E-ISSN 1433-2965, Vol. 27, S60-S60 p.Article in journal, Meeting abstract (Other academic) Published
National Category
Endocrinology and Diabetes Orthopaedics
Identifiers
urn:nbn:se:uu:diva-299778 (URN)000376469100048 ()
Conference
WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, APR 14-17, 2016, Malaga, SPAIN
Available from: 2016-07-27 Created: 2016-07-27 Last updated: 2018-01-10Bibliographically approved
Lindahl, K., Kindmark, A., Rubin, C.-J., Malmgren, B., Grigelioniene, G., Soderhall, S., . . . Åstrom, E. (2016). Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone, 87, 11-18.
Open this publication in new window or tab >>Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate
Show others...
2016 (English)In: Bone, ISSN 8756-3282, E-ISSN 1873-2763, Vol. 87, 11-18 p.Article in journal (Refereed) Published
Abstract [en]

Background: Osteogenesis imperfecta (OI) is an inherited heterogeneous bone fragility disorder, usually caused by collagen I mutations. It is well established that bisphosphonate treatment increases lumbar spine (LS) bone mineral density (BMD), as well as improves vertebral geometry in severe 01; however, fracture reduction has been difficult to prove, pharmacogenetic studies are scarce, and it is not known at which age, or severity of disease, treatment should be initiated.

Materials and methods: COL1A1 and COL1A2 were analyzed in 79 children with OI (type I n = 33, type III n = 25 and type IV n = 21) treated with Pamidronate. Data on LS BMD, height, and radiologically confirmed non vertebral and vertebral fractures were collected prior to, and at several time points during treatment.

Results: An increase in LS BMD Z-score was observed for all types of OI, and a negative correlation to A LS BMD was observed for both age and LS BMD Z-score at treatment initiation. Supine height Z-scores were not affected by Pamidronate treatment, The fracture rate was reduced for all OI types at all time points during treatment (overall p < 0.0003, < 0.0001 and 0.0003 for all 01 types 1, III and IV respectively). The reduced fracture rate was maintained for types I and IV, while an additional decrease was observed over time for type III. The fracture rate was reduced also in individuals with continued low BMD after >4 yrs Pamidronate. Twice as many boys as girls with 01 type I were treated with Pamidronate, and the fracture rate the year prior treatment was 2.2 times higher for boys (p = 0.0236). Greater Delta LS BMD, but smaller Delta fracture numbers were observed on Pamidronate for helical glycine mutations in COL1A1 vs. COL1A2. Vertebral compression fractures did not progress in any individual during treatment; however, they did not improve in 9%, and these individuals were all >11 years of age at treatment initiation. (p < 0.0001).

Conclusion: Pamidronate treatment in children with all types of 01 increased LS BMD, decreased fracture rate, and improved vertebral compression fractures. Fracture reduction was prompt and maintained during treatment, irrespective of age at treatment initiation and collagen I mutation type.

Keyword
Osteogenesis imperfecta, Bisphosphonate, Fracture, Pharmacogenetics, Mutation, Collagen type I
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-298060 (URN)10.1016/j.bone.2016.02.015 (DOI)000376055100002 ()26957348 (PubMedID)
Note

Funding: We thank all of the individuals with 01 who participated in this study. Furthermore, we thank Anna-Lena Johansson, Elin Carlsson and Catharina Kumlien and Anna Hammarsjo for skillful technical assistance. Funding was received from the Swedish research council, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet; by grants from Crown-Princess Lovisa, Axel Tiellmans Minnesfond, Samariten, Sallskapet Barnavard and Promobilia, Norrbacka Eugenia, Promobilia, RBU and Sunnerdahls foundations.

Available from: 2016-06-30 Created: 2016-06-29 Last updated: 2017-11-28Bibliographically approved
Feudjo Tepie, M., Banefelt, J., Ström, O., Ortsater, G., Ljunggren, Ö., Åkesson, K., . . . Wagman, R. B. (2016). Denosumab (DMAB) Freedom Extension Pseudo Control Study: A Retrospective Cohort Study Of Comorbidities In Swedish Women With Postmenopausal Osteoporosis (PMO). Paper presented at WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, APR 14-17, 2016, Malaga, SPAIN. Osteoporosis International, 27, S154-S154.
Open this publication in new window or tab >>Denosumab (DMAB) Freedom Extension Pseudo Control Study: A Retrospective Cohort Study Of Comorbidities In Swedish Women With Postmenopausal Osteoporosis (PMO)
Show others...
2016 (English)In: Osteoporosis International, ISSN 0937-941X, E-ISSN 1433-2965, Vol. 27, S154-S154 p.Article in journal, Meeting abstract (Other academic) Published
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-299780 (URN)000376469101150 ()
Conference
WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, APR 14-17, 2016, Malaga, SPAIN
Available from: 2016-07-27 Created: 2016-07-27 Last updated: 2017-11-28Bibliographically approved
Organisations

Search in DiVA

Show all publications